Stem cell treatments could come by 2005

韩雪娜

日期: 2002-10-25 今日/总浏览: 1/15628 J- ~, R5 ?: e* h
. Y( Z5 q% c8 U/ U
2 q+ ^8 W) O3 v
+ {1 S$ V7 O4 W0 w: F5 i

4 ]' {8 \4 _; ]! _8 A8 WThefirstcommerciallyavailablestemcell-derivedproductslikelywillcomefromadultstemcellsandbeforthetreatmentofneurologicaldisorderssuchasParkinson'sandAlzheimer'sdisease,theheadofanadultstemcellcompanytoldUnitedPressInternational.
8 r; _8 \0 r# |Theproductscouldbeavailableinthenextthreeyears,saidMartinMcGlynn,presidentandchiefexecutiveofficerofStemCellsInc.,ofPaloAlto,Calif.,whichisworkingtodevelopmedicaltreatmentsderivedfromadultstemcells.McGlynnwasexpectedtomakesimilarremarksatTechvest's4thAnnualHealthcareConference&ExpoinBostonWednesday.
1 O) U: x- b8 M2 MStemcellshavetheabilitytogiverisetodifferentcelltypesinthebody.Theyhavethepotentialtoreplacetissuesdamagedbydisease.3 H3 u9 u7 E0 O- o2 ~
Embryonicstemcellscangiverisetoanycelltypeandthushavethegreatestpotentialtotreatthewidestrangeofdiseases.However,theyarecontroversialbecauseharvestingthemrequiresthedestructionofembryos.Adultstemcells,whichcanbederivedfromadulttissueswithoutharmingthedonor,offeralesscontroversialalternative,althoughtheycangiveriseonlytoalimitednumberofcelltypes.
# o# J/ @- ]! a  hMypredictionisthat...we'relikelytoseeoneortwostemcellproductsonthemarketinthisdecade,McGlynnsaid.Productsderivedfromadultstemcellsarelikelytobethefirstproductsbecausethesearefurtheralonginthedevelopmentprocessanddon'thavealltheregulatoryhurdlesthatareassociatedwithembryonicstemcells,hesaid.$ v) p; @; N3 L4 T, K6 D! v- w
Suchproductsprobablywillappearonthemarketstartingfromaround2005andcontinuinginthebackhalfofthisdecade,hesaid.
6 Q9 B' G' N! k! z5 l  SMcGlynnpredictedthefirstproductswouldbetreatmentsfordegenerativediseasesofthecentralnervoussystem,includingParkinson's,Alzheimer's,strokeandparalysis.. n* [+ l; e0 U* H+ S8 b
Iwouldagreewith(McGlynn)thatsomeoftheearliestproductstoreachcommercializationwillbeforneurologicaldisorders,LindaPowers,managingdirectorofToucanCapital,aventurecapitalfirminBethesda,Md.,toldUPI.It'sstillupintheairwhether(thefirstproducts)willbeadultorembryonicstemcells,addedPowers,whosefirmhasmadeinvestmentsinbothadultandembryonicstemcellcompanies.
# l, F4 i2 G7 x7 M% E* RWereallyarelookingacrosstheboardatadultandembryonicstemcells,Powerssaid.We'renottiltingonewayortheother.Wewanttoseewhatlookslikeitproducesthebestresultsandgofromthere.It'stooearlytotellwhichlineofcellswillbethefirsttoreachthemarket,sheadded.5 s1 |; X: o- o4 y9 r7 ~3 {
McGlynnsaidheexpectsembryonicstemcellseventuallytobecommercializedaswell.Subjecttotheavailabilityofcapital,Iwouldanticipateembryonicstemcellsciencewillcontinuetobeworkedonandimproved,hesaid.Overtime,scientistsmightlearnhowtofullyunlockthepotentialofembryonicstemcellsanddevelopthemasdiseasetreatments,hesaid.
0 I8 u# ^9 u  ADependingoneconomicsandthedisease-treatingcapabilityofeachcellline,McGlynnadded,Wecouldhaveboth(adultandembryonicstemcell-derivedproducts)outthereonthemarket.
) t: ~0 J+ G' b9 T
# N, r' ]7 U+ C& ?$ ~  |; l& [
: C. D" U/ N( u* \. M
8 _4 H6 q' {. {
: t* i: Y1 g, ~
5 X/ X5 U! Q/ `# w# @2 ]作者: Steve Mitchell. T5 `, r6 O8 W
来源: UPI Medical Correspondent
6 R; D! R$ k) x$ f( J* k发布者: 刘斌